Skip to content

Ardelyx ARDX Product sales, net — Cost of Sales

Similar metrics at other companies

Travere Therapeutics, Inc. logo
TVTXTotal net product sales — Cost of goods sold
$1.95M+55.6%
Mirum Pharmaceuticals, Inc. logo
MIRMCost of Sales
$28.81M+25.1%
LQD
LQDAProduct — Cost of Goods Sold
$11.08M
Syndax Pharmaceuticals logo
SNDXCost Of Product Sales
$2.63M+198%
Cactus logo
WHDProduct revenue — Cost of Sales
$4.41M+8.3%
Biogen logo
BIIBProduct revenue, net — Cost of sales, excluding amortization and impairment of acquired intangible assets
$478.7M+3.6%

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.53B+25.5%
Enterprise value$1.71B+27.1%
P/S3.6×+0.2×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%
Net margin-13.6%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-39.5%
Debt / equity1.4×+0.3×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The official record: Ardelyx’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's product sales, net — cost of sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's product sales, net — cost of sales?
Ardelyx (ARDX) reported product sales, net — cost of sales of $2.88M in Q1 2026.
How has Ardelyx's product sales, net — cost of sales changed year-over-year?
Ardelyx's product sales, net — cost of sales increased by 22.9% year-over-year, from $2.34M to $2.88M.
What does product sales, net — cost of sales mean?
This metric represents the direct costs incurred to manufacture and deliver the pharmaceutical products sold during the reporting period. It includes expenses such as raw materials, manufacturing labor, and distribution costs directly attributable to product sales. Analyzing this figure provides insight into the company's gross margin efficiency and the scalability of its commercial operations.